Johnson & Johnson (NYSE: JNJ) disclosed that it has earned the emergency use authorization for its single-dose COVID-19 vaccine. The firm disclosed that it has applied for emergency use authorization for its COVID-19 vaccine. The single-dose COVID-19 vaccine will be delivered to India through a supply contract with homegrown vaccine maker Biological E Ltd.
Currently, AstraZeneca (AZN.L), Bharat Biotech, Russia's Gamaleya Institute, and Moderna (MRNA.O) have received the authorization. India has disclosed that it has recorded an average of 30,000 to 40,000 new coronavirus cases every day since July. The federal government has cautioned that although cases have dropped from a high of 400,000 daily at the height of the lethal second wave, the danger has not fallen yet.
Shares of Johnson & Johnson (NYSE: JNJ) plunged 0.33% as it has lost -0.58 during the trading session of Friday. In the past 52-week of the trading session, the share of the firm went from a low point around $133.65 and a high point around $174.59 from its 52-week low and high range, respectively. JNJ has a total market capitalization of $$455.81 billion at the time of writing.
Furthermore, earlier, JNJ disclosed that it was in discussion with the Indian government to hasten the availability of its vaccine, without giving further details. Moreover, Indian Health Ministry revealed that only about 495.3 million people from a population of more than 1.3 billion had got at least one dose of the vaccine.